From a cost-effectiveness perspective, these drugs would have to translate to striking long-term health benefits for patients, such as a reduction in major cardiac events or an overall increase in time to dialysis
Recent clinical trials have shown that dual and triple agonists targeting these pathways can lead to superior reductions in body weight and liver fat compared to GLP-1R mono-agonists, with a comparable safety profile [16,17,18,19,20,21,22]
Semaglutide GLP-1 injections are designed to help patients lose weight in the short term, and Flawless MedSpa encourages lifestyle changes such as exercising and eating healthy for long-term success
It is investigational and is being studied in Eli Lilly's Phase 3 TRIUMPH (obesity-focused) and TRANSCEND-T2D (type 2 diabetes) programs
On the other hand, in the retrospective cohort study using TriNetX Analytics Network electronic health records, semaglutide significantly lowered the risk of both new (HR, 0.27
Its not a substitute for prescription therapy